SCHEMBL18324922

SCHEMBL18324922

Cc1ccc(-c2ccc(-c3cc(F)c(C(F)(F)Oc4cc(F)c(OC(F)(F)F)c(F)c4)c(F)c3)c(F)c2)cc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
AKR1C3 P42330 3/20 0.35
AKR1C2 P52895 3/20 0.35
FFAR4 Q5NUL3 3/20 0.34
GRM2 Q14416 1/20 0.32
PTGS2 P35354 4/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
AKR1B10 O60218 1/20 0.32
AKR1C4 P17516 1/20 0.32
AKR1C1 Q04828 1/20 0.32
PTGS1 P23219 1/20 0.32
FFAR1 O14842 2/20 0.31
ERN1 O75460 1/20 0.31
PDE3B Q13370 1/20 0.30
PDE3A Q14432 1/20 0.30
APP P05067 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18324945 0.93 AKR1C3 (0.35) ALOX5APFEN1AKR1C3AKR1C2PTGS2
SCHEMBL18324939 0.93 KDM4E (0.34) ALOX5APFEN1FFAR4PTGS2KDM4E
SCHEMBL20118151 0.89 ALOX5AP (0.37) ALOX5APFEN1AKR1C3AKR1C2FFAR4
SCHEMBL18324924 0.89 AKR1C3 (0.37) ALOX5APFEN1AKR1C3AKR1C2PTGS2
SCHEMBL18324942 0.89 AKR1C3 (0.37) ALOX5APFEN1AKR1C3AKR1C2PTGS2
SCHEMBL18324925 0.88 KDM4E (0.32) PTGS2KDM4EGAAMAPTMAPK1
SCHEMBL18324921 0.84 AKR1C3 (0.34) ALOX5APFEN1AKR1C3AKR1C2FFAR4
SCHEMBL18855112 0.84 AKR1C3 (0.34) ALOX5APFEN1AKR1C3AKR1C2PTGS2
SCHEMBL20118273 0.84 GRM2 (0.39) ALOX5APFEN1FFAR4GRM2FFAR1
SCHEMBL21063847 0.83 GPR3 (0.43) ALOX5APFEN1AKR1C3AKR1C2FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9862886-B2 Compound, liquid crystal composition including the same, and liquid crystal display device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2018-01-09 US disclosed
US-20160369167-A1 COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2016-12-22 US disclosed
US-20160369167-A1 COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160369167-A1 COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME SCO2, NCAPD3, OCIAD2 ALOX5AP 2571/4885FEN1 3471/4885AKR1C3 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.